Cargando…

Post-COVID-19 irritable bowel syndrome: an integrative review

INTRODUCTION: the persistence of long-term symptoms of COVID-19 represents a new challenge for the medical-scientific community, it is the condition called long-term COVID-19. Irritable Bowel Syndrome (IBS) is one of the most common Disorders of the Gut-Brain Interaction and its post-infection devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Julyanne Tereza Cordeiro, da Fonseca, Olival Cirilo Lucena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Colégio Brasileiro de Cirurgiões 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644864/
https://www.ncbi.nlm.nih.gov/pubmed/37991064
http://dx.doi.org/10.1590/0100-6991e-20233618-en
_version_ 1785134639573106688
author Silva, Julyanne Tereza Cordeiro
da Fonseca, Olival Cirilo Lucena
author_facet Silva, Julyanne Tereza Cordeiro
da Fonseca, Olival Cirilo Lucena
author_sort Silva, Julyanne Tereza Cordeiro
collection PubMed
description INTRODUCTION: the persistence of long-term symptoms of COVID-19 represents a new challenge for the medical-scientific community, it is the condition called long-term COVID-19. Irritable Bowel Syndrome (IBS) is one of the most common Disorders of the Gut-Brain Interaction and its post-infection development is already validated. According to the Rome IV criteria, it is characterized by the presence of recurrent abdominal pain, on average, at least 1 day a week in the last 3 months with onset of symptoms at least 6 months before diagnosis, associated with 2 or more factors: related to defecation and/or associated with change in stool frequency and/or associated with change in stool form. This study aimed to review data on post-COVID-19 IBS. METHODS: this is an integrative review of studies published between January 1, 2020 and April 30, 2023, which presented data on IBS with previously diagnosed COVID-19 disease. The PubMed database was used, the descriptors were “Irritable bowel syndrome” AND “COVID-19”; the reference list of the articles was also retrieved. RESULTS: eight studies were reviewed, it was observed that 0.6% to 11.6% of patients had IBS again after a minimum period of 6 months of infection. Risk factors were female gender, severity of COVID-19, presence of acute-phase gastrointestinal symptoms, and depression/anxiety. CONCLUSION: the results obtained suggest that COVID-19 may be associated with the emergence of de novo IBS. Further studies are needed to investigate its long-term effects and clinical spectra.
format Online
Article
Text
id pubmed-10644864
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Colégio Brasileiro de Cirurgiões
record_format MEDLINE/PubMed
spelling pubmed-106448642023-11-10 Post-COVID-19 irritable bowel syndrome: an integrative review Silva, Julyanne Tereza Cordeiro da Fonseca, Olival Cirilo Lucena Rev Col Bras Cir Review Article INTRODUCTION: the persistence of long-term symptoms of COVID-19 represents a new challenge for the medical-scientific community, it is the condition called long-term COVID-19. Irritable Bowel Syndrome (IBS) is one of the most common Disorders of the Gut-Brain Interaction and its post-infection development is already validated. According to the Rome IV criteria, it is characterized by the presence of recurrent abdominal pain, on average, at least 1 day a week in the last 3 months with onset of symptoms at least 6 months before diagnosis, associated with 2 or more factors: related to defecation and/or associated with change in stool frequency and/or associated with change in stool form. This study aimed to review data on post-COVID-19 IBS. METHODS: this is an integrative review of studies published between January 1, 2020 and April 30, 2023, which presented data on IBS with previously diagnosed COVID-19 disease. The PubMed database was used, the descriptors were “Irritable bowel syndrome” AND “COVID-19”; the reference list of the articles was also retrieved. RESULTS: eight studies were reviewed, it was observed that 0.6% to 11.6% of patients had IBS again after a minimum period of 6 months of infection. Risk factors were female gender, severity of COVID-19, presence of acute-phase gastrointestinal symptoms, and depression/anxiety. CONCLUSION: the results obtained suggest that COVID-19 may be associated with the emergence of de novo IBS. Further studies are needed to investigate its long-term effects and clinical spectra. Colégio Brasileiro de Cirurgiões 2023-11-10 /pmc/articles/PMC10644864/ /pubmed/37991064 http://dx.doi.org/10.1590/0100-6991e-20233618-en Text en © 2023 Revista do Colégio Brasileiro de Cirurgiões https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Review Article
Silva, Julyanne Tereza Cordeiro
da Fonseca, Olival Cirilo Lucena
Post-COVID-19 irritable bowel syndrome: an integrative review
title Post-COVID-19 irritable bowel syndrome: an integrative review
title_full Post-COVID-19 irritable bowel syndrome: an integrative review
title_fullStr Post-COVID-19 irritable bowel syndrome: an integrative review
title_full_unstemmed Post-COVID-19 irritable bowel syndrome: an integrative review
title_short Post-COVID-19 irritable bowel syndrome: an integrative review
title_sort post-covid-19 irritable bowel syndrome: an integrative review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644864/
https://www.ncbi.nlm.nih.gov/pubmed/37991064
http://dx.doi.org/10.1590/0100-6991e-20233618-en
work_keys_str_mv AT silvajulyanneterezacordeiro postcovid19irritablebowelsyndromeanintegrativereview
AT dafonsecaolivalcirilolucena postcovid19irritablebowelsyndromeanintegrativereview